4/A: Cumberland Pharmaceuticals Director Amends Filing to Correct Share Acquisition

A director of Cumberland Pharmaceuticals, James Jones, amended a previous filing to correct the number of shares acquired on March 25, 2024, increasing the reported amount from 1,000 to 2,500.

Summary

• This document is an amended SEC Form 4 filing by James Jones, a director at Cumberland Pharmaceuticals.
• The amendment corrects an error in the original filing from March 26, 2024, regarding the number of shares acquired on March 25, 2024.
• The original filing incorrectly stated that 1,000 shares were acquired, but the correct number is 2,500 shares.
• This correction increases the reported acquisition by 1,500 shares.

Sentiment

Score: 7

Explanation: The document is a routine correction of a filing, indicating no significant positive or negative sentiment. It reflects standard regulatory compliance.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company director, which is a common occurrence in the pharmaceutical industry.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders across all publicly traded companies.
• The correction of an error in a previous filing is not uncommon and is part of the regulatory compliance process.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding the director's holdings.

Key Dates

Keywords

SEC Form 4, Beneficial Ownership, Cumberland Pharmaceuticals, Share Acquisition, Director, Amendment, CPIX